New theranostic approach effectively detects and treats neuroendocrine prostate cancer

A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy. Because this disease is often poorly visualized with prostate-specific membrane antigen (PSMA)-based imaging, the RET approach offers an important alternative when conventional molecular imaging and PSMA-directed therapies are unsuitable. This research is being presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.